Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02161718 · ClinicalTrials.gov registry record · Phase 2
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
A Phase 2 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT02161718 is a Phase 2 study that has completed, run by Alkermes. The registered enrollment target is 300 participants.
The verdict
NCT02161718, a Phase 2 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).
Interventions
- DRUG Samidorphan + olanzapine (ALKS 3831)
- DRUG Placebo + olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02161718
The ClinicalTrials.gov registry entry for NCT02161718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Samidorphan + olanzapine (ALKS 3831) is the first listed.
NCT02161718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02161718 about?
NCT02161718 is a clinical study titled "A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder". This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).
What is the current status of trial NCT02161718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2014-05. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02161718?
The interventions under investigation include: Samidorphan + olanzapine (ALKS 3831) (DRUG), Placebo + olanzapine (DRUG).
Who is sponsoring clinical trial NCT02161718?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.